TABLE 1.
Description of demographic and clinical characteristics of the study patients (N=220).
| Demographic and clinical characteristics | Value |
|---|---|
| Demographics | |
| Sex female, n (%) | 120 (54.5) |
| Median age at first MG symptom, years (P25–P75) | 60.5 (44.3–73.0) |
| Median age at first visit, years (P25–P75) | 70.0 (56–83) |
| Clinical characteristics | |
| Time from first symptom to diagnosis, months (SD) | 8.8 (21.3) |
| Time from baseline visit to diagnosis, days a (SD) | 48 (132.0) |
| Autoimmunity, n (%) b | |
| Anti‐AChR | 186 (84.5) |
| Anti‐MuSK | 13 (5.9) |
| Seronegative | 22 (10.0) |
| Baseline MGFA clinical classification, n (%) | |
| I | 77 (35.0) |
| IIA | 48 (21.8) |
| IIB | 58 (26.4) |
| IIIA | 7 (3.2) |
| IIIB | 17 (7.7) |
| IVA | 1 (0.5) |
| IVB | 9 (4.1) |
| V | 3 (1.4) |
| MGFA class at maximal worsening during the study follow‐up, n (%) | |
| IIA | 48 (21.8) |
| IIB | 49 (22.3) |
| IIIA | 34 (15.5) |
| IIIB | 47 (21.4) |
| IVA | 5 (2.3) |
| IVB | 24 (10.9) |
| V | 13 (5.9) |
| Drug refractory status during study follow‐up, n (%) | 22 (10.0) |
| Death during study period n, (%) | 27 (12.3) |
Abbreviations: AChR, acetylcholine receptor; MG, myasthenia gravis; MGFA, Myasthenia Gravis Foundation of America; MuSK, muscle‐specific kinase; P, percentile; SD standard deviation.
a
Among the 133 (60.5%) patients who were diagnosed after their first visit.
b
One patient was anti‐AChR‐positive and anti‐MuSK‐positive.